ResearcherPfizer (United States)No recent work listed

Guoyun Zhu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5113641646. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2019: 2 papers

Papers 2

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. Co-author DOI 10.1038/s41598-019-44874-0 ↗
Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. Co-author DOI 10.1038/s41598-019-53130-4 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shu‐Hui Liu · 1 shared paper, 2019 · strength 0.07
- Paper Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic… DOI 10.1038/s41598-019-53130-4 ↗
Xiaohui Liu · 1 shared paper, 2019 · strength 0.07
- Paper Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic… DOI 10.1038/s41598-019-53130-4 ↗
Shuhui Liu · 1 shared paper, 2019 · strength 0.07
- Paper Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. DOI 10.1038/s41598-019-44874-0 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.